BRO vs DMAC · P/E 30, rev $4.80B vs $157.4M cap
Brown & Brown Inc (BRO) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
Brown & Brown Inc (BRO) is a insurance brokers company listed on US.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported BRO revenue for 2024-12-31 was $4.80B. Net income was $1.00B. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. BRO currently screens at market cap $35.56B and trailing P/E 30.0.
DMAC does not have a complete income-statement cache yet.
BRO currently screens at market cap $35.56B and trailing P/E 30.0. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the BRO and DMAC stock pages for the full models.
Not investment advice.